[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Milan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":551},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,48,79,116,139,166,187,207,242,267,292,313,336,363,389,414,439,474,500,523],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054134","appropriateness-of-hemostatic-agent-use-in-cardiovascular-surgery-haemovax-100054134",false,"NCT07699016","Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)","Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study","HAEMOVAX","Inclusion Criteria:\n\n* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents\n* Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months)\n* Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire\n\nExclusion Criteria:\n\n* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals)\n* Surgeons not involved in operative cardiovascular practice during the study period\n* External collaborators or visiting surgeons without regular clinical activity at the institution\n* Individuals who do not provide informed consent for participation in the anonymous survey\n* Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score",true,"ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","OBSERVATIONAL","Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making.\n\nHAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.",[26,27,28,29,30],"Hemostasis","Perioperative Bleeding","Cardiovascular Surgery","Cardiac Surgery","Vascular Surgery",[32,33,34,27],"Hemostatic Agents","Surgical Hemostasis","Topical Hemostatic Agents","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"University of Milan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100643637","effect-of-high-flow-nasal-therapy-hfnc-weaning-protocols-vs-standard-of-care-on-respiratory-outcomes-in-patients-with-acute-respiratory-failure-100643637","NCT07638293","Effect of High Flow Nasal Therapy (HFNC) Weaning Protocols vs Standard of Care on Respiratory Outcomes in Patients With Acute Respiratory Failure","Effect of High Flow Nasal Therapy (HFNC) Weaning Protocols vs Standard of Care on Respiratory Outcomes in Patients With Acute Respiratory Failure: A Randomized Clinical Trial","WHIP","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of acute respiratory failure (ARF)\n* Receiving HFNC treatment for ≥24 hours\n\nExclusion Criteria:\n\n* Post-extubation HFNC use or tracheostomized patients\n* Respiratory acidosis (pH \\\u003C7.35) or clinically significant acute hypercapnia (pCO₂ \\>50 mmHg with worsening from baseline)\n* Long-term home NIV or home CPAP use\n* Do-not-intubate (DNI) orders precluding escalation to invasive mechanical ventilation\n* Life expectancy ≤48-72 hours due to terminal non-respiratory disease\n* Neurological impairment or deep sedation preventing safe HFNC use (e.g. coma or severe uncontrolled delirium)\n* Technical contraindications to HFNC (i.e. facial trauma, maxillofacial surgery, severe nasal obstruction)\n* Refusal to participate or inability to provide informed consent",{"count":57,"type":22},148,"INTERVENTIONAL",[60],"NA","High-flow nasal cannula (HFNC) is a widely used noninvasive respiratory support technique for patients with acute respiratory failure (ARF). It provides heated and humidified oxygen at high flow rates, improving oxygenation, reducing respiratory effort, and enhancing patient comfort. International guidelines recommend HFNC over conventional oxygen therapy in hypoxemic ARF. However, there is significant variability in clinical practice regarding HFNC discontinuation, and no standardized weaning criteria currently exist. Prolonged HFNC use may increase hospital stay and healthcare costs, while premature discontinuation may lead to respiratory deterioration and the need for further ventilatory support. Previous studies suggest that successful HFNC weaning may be predicted by a Fraction of inspired oxygen (FiO₂) ≤40% and a Respiratory rate-Oxygenation index (ROX index) ≥9.2. The ROX index is calculated as the ratio of peripheral oxygen saturation (SpO₂) divided by fraction of inspired oxygen (FiO₂) to respiratory rate. The primary objective of this study is to compare a standardized HFNC weaning strategy based on ROX index and FiO₂ thresholds with usual clinical practice based on physician judgment. The primary outcome is weaning failure at the first attempt, defined as the need for HFNC reinstitution, noninvasive or invasive mechanical ventilation, or death within 48 hours after discontinuation.",[63],"Acute Respiratory Failure (ARF)",[65,66,67,68,69],"ARF","HFNC","acute respiratory failure","weaning","ROX INDEX","2026-06-04",{"date":72,"type":39},"2026-06-10",{"date":74,"type":22},"2026-05-15",{"date":76,"type":22},"2028-05",{"name":45,"class":46},2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":99,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851","NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy",{"count":88,"type":22},427,"Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[91,92,93,94,95,96,97,98],"Interstitial Lung Disease (ILD)","Bronchoscopy","Bronchoalveolar Lavage (BAL)","Acute Exacerbation","Cryobiopsy","Transbronchial Biopsy","Endosonography","Pulmonary Fibrosis",[100,101,102,103,104,105,106],"ILD","BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","NOT_YET_RECRUITING","2026-05-29",{"date":70,"type":39},{"date":111,"type":22},"2026-06-01",{"date":113,"type":22},"2028-05-30",{"name":45,"class":46},11,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":18,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":47},"100468563","effect-on-bronchodilation-response-and-ventilation-heterogeneity-of-different-inhalation-volumes-in-copd-100468563","NCT05381415","Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD","Effect on Bronchodilatation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD: the BREATH COPD Study","BREATH COPD","Inclusion Criteria:\n\n* age above 40 years old;\n* history of smoking equal or above 10 PKYs;\n* VEMS after bronchodilatation ≤ 70%,\n* medical Necessity to perform a bronchodilatation test.\n\nExclusion Criteria:\n\n* history of bronchial asthma or other chronic respiratory diseases such as pulmonary fibrosis;\n* uncontrolled cardiovascular diseases at the time of the visit;\n* current pregnancy;\n* incapacity to execute lung function tests for cognitive impairment, substance abuse or claustrophobia;\n* known hypersensitivity or intolerance to salbutamol.","40 Years",{"count":126,"type":22},30,"During bronchodilator tests, it's common to ask patients with asthma or chronic obstructive pulmonary disease (COPD) to take bronchodilator therapy by inhaling after a maximal exhalation, when the respiratory system volume equals the residual volume. The same maneuver is required for the chronic therapy.\n\nNevertheless, in patients with COPD the distribution of ventilation is more heterogeneous, especially when lung volumes are closer to residual volume . It is therefore predictable that the distribution of air volume containing bronchodilator that has been inhaled at residual volume is more heterogeneous than at higher volumes, such as at functional residual capacity. Accordingly, the bronchodilator can be preferentially distributed in more open airways than in less patent ones, with a heterogeneous distribution of the medication. Therefore, the overall bronchodilation should be greater when the drug inhalation is performed at functional residual capacity than at residual volume.\n\nIt is common knowledge that the effectiveness of bronchodilator therapy with pMDI in subjects with COPD is greatly affected by the inhalation technique, which can be difficult to perform for many patients. Therefore, in addition to the possibility that inhalation of bronchilation therapy at residual volume could lower the drug effectiveness, this maneuver complicates the sequence of actions required to the patient, enhancing the risk of errors and decreasing the aderence to treatment.\n\nThe aim of this study is to investigate whether the inhalation of a bronchodilator at different lung volumes can affect its effectiveness in terms of respiratory function, in patients with COPD.\n\nAssuming that the bronchodilator effectiveness is equal or greater when inhaled at functional residual capacity rather than at residual volume, the inhalation maneuver can be simplified for patients with COPD.",[129,130],"COPD","Lung Injury","2026-04-28",{"date":133,"type":39},"2026-05-04",{"date":135,"type":22},"2026-12-01",{"date":137,"type":22},"2027-12-30",{"name":45,"class":46},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":18,"minAge":124,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":58,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":165,"locationsCount":47},"100380794","phase-4-effect-of-add-on-doxofylline-on-lung-function-in-stable-copd-100380794","NCT04238221","Effect of add-on Doxofylline on Lung Function in Stable COPD","Effect of Doxofylline on Bronchial Obstruction, in add-on to Maximal Inhalation Therapy, in Clinically Stable COPD Patients.","EDAI","Inclusion Criteria:\n\n* COPD diagnosis for at least 6 months, according to current European Respiratory Society guidelines\n* baseline FEV1 ≤ 80% of predicted value\n* active or former smokers with smoking history ≥ 10 pack-years\n* patients chronically treated with a long acting muscarinic antagonist (LAMA) and a long acting beta-2 agonists (LABA), in association with or without an inhaled corticosteroid (ICS)\n* clinically stable disease for 6 months.\n\nExclusion Criteria:\n\n* previous or current diagnosis of bronchial asthma\n* previous lung volume reduction through surgery or endobronchial valves\n* inability to perform respiratory function tests according to international standards, or contraindications to perform 6-minute walking test\n* known allergy or intolerance to doxofylline\n* current or potential pregnancy\n* mini-Mental test \\\u003C21\n* congestive heart failure NYHA III or IV\n* recent (\\\u003C6 months) myocardial infarction\n* unstable arrhythmias\n* chronic hypotension\n* active peptic ulcer\n* severe liver disease\n* active neoplasia\n* history of drug or alcohol abuse.",{"count":148,"type":22},78,[150],"PHASE4","It is a phase IV, prospective, interventional, single blind, randomized, crossover trial in which the investigators will evaluate the effects of a 4-week treatment with doxofylline 400 mg bid, in add-on to maximal inhalation therapy, in clinically stable COPD patients.",[153],"Chronic Obstructive Pulmonary Disease",[129,155,156,157,158,159,160],"Bronchodilator","Pulmonary Function Test","Doxofylline","Methylxanthines","6-minute walk test","FEV1",{"date":162,"type":39},"2026-04-29",{"date":135,"type":22},{"date":137,"type":22},{"name":45,"class":46},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":47},"100613940","the-effect-of-prolonged-sugar-free-chewing-gum-mastication-on-self-reported-fatigue-levels-and-changes-of-static-and-dynamic-surface-electromyography-parameters-in-young-individuals-with-and-without-temporomandibular-joint-disorders-100613940","NCT07273123","The Effect of Prolonged Sugar-Free Chewing Gum Mastication on Self-Reported Fatigue Levels and Changes of Static and Dynamic Surface Electromyography Parameters in Young Individuals With and Without Temporomandibular Joint Disorders.","Effect of Sugar-Free Chewing Gum Mastication on Fatigue of the Masticatory Muscles in Young Adults With and Without Temporomandibular Joint Disorders","Inclusion criteria (both groups):\n\n* Age 19-35 years\n* Chewing-gum users, even occasional\n* Good general health\n* Good oral health\n\nInclusion criteria (Healthy controls):\n\n\\- no diagnosed temporomandibular joint disorders\n\nInclusion criteria (study group)\n\n\\- diagnosed temporomandibular joint disorders\n\nExclusion criteria (both groups):\n\n* Non chewing gum users\n* History of neurological disorders\n* History of musculoskeletal diseases\n* History of facial or cervical injuries\n* Presence of cervical pain\n* Two or more missing teeth\n* Current treatment with fixed or removable orthodontic appliances\n* Active periodontal disease\n* Presence of cavitated carious lesions","19 Years","35 Years",{"count":126,"type":22},"This case-control study investigates fatigue induced by prolonged gum mastication in individuals with temporomandibular disorders (TMD). The study addresses two primary questions:\n\nHow does self-reported fatigue, measured with a visual analogue scale (VAS), change during sustained chewing? How do static and dynamic surface electromyographic (sEMG) parameters evolve over the same period? Participants with TMD will be compared with healthy controls to determine group differences in perceived fatigue and EMG responses.\n\nAll participants will undergo baseline EMG assessment, then chew sugar-free gum continuously for 3 minutes, alternating sides without rest. After each 3-minute interval, static and dynamic EMG recordings will be obtained and participants will rate their fatigue on the VAS. This cycle may be repeated up to six times (maximum 18 minutes). Participants are free to stop chewing at any time if fatigue becomes intolerable.",[178],"Temporomandibular Joint Disorder","2026-04-27",{"date":181,"type":39},"2026-05-01",{"date":183,"type":39},"2025-10-01",{"date":185,"type":22},"2026-07-30",{"name":45,"class":46},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":47},"100589894","long-term-clinical-outcome-after-arthroscopic-rotator-cuff-repair-augmentation-with-autologous-microfragmented-lipoaspirate-tissue-100589894","NCT06960343","Long Term Clinical Outcome After Arthroscopic Rotator Cuff Repair Augmentation With Autologous Microfragmented Lipoaspirate Tissue","Long Term Clinical Outcome After Arthroscopic Rotator Cuff Repair Augmentation With Autologous Microfragmented Lipoaspirate Tissue: a Prospective Randomized Controlled Trialin Question Won by Our Research Group.","Inclusion Criteria:\n\n* Age \\> 18 years\n* Full-thickness supraspinatus and infraspinatus tendon tears (C1, C2, and C3 according to the SCOI classification)\n* Indication for arthroscopic rotator cuff repair\n* Informed consent to participate in the study\n* Informed consent to participate for the duration of the study\n\nExclusion Criteria:\n\n* Partial rotator cuff tendon tears (A1, A2, A3, B1, B2, and B3 according to the SCOI classification)\n* Massive rotator cuff tear (C4 according to the SCOI classification)\n* Subscapularis tendon tear (grade III, IV, or IV according to Lafosse classification)\n* Associated anterior, posterior, or multidirectional shoulder instability\n* Indication for repair of a SLAP lesion of the biceps anchor\n* Grade III or IV muscle atrophy of the supraspinatus and infraspinatus tendons (according to Goutallier or Fuchs classification)\n* Intra-articular hyaluronic acid or corticosteroid infiltration within 3 mo from the planned surgical procedure\n* Medical comorbidities contraindicating arthroscopic shoulder surgery\n* Local (shoulder, abdominal region, gluteal region) or systemic infection, osteomyelitis, or sepsis\n* Diabetes mellitus, untreated thyroid disease, chronic kidney disease, rheumatoid arthritis\n* Immunodeficiency\n* Chronic disorders involving coagulation, platelet aggregation, or severe coagulopathy\n* Severe cardiovascular disease\n* Stroke or acute cardiovascular event within 6 mo from the planned surgical procedure\n* Weight loss for any cause .30 kg in 12 mo or .10 kg in 12 mo without a cause\n* Eating disorders or body dysmorphic disorder\n* Varices, phlebitis, or scars next to the planned adipose tissue harvesting site\n* Alcohol\u002Fdrug addiction or psychiatric disease compromising compliance with postoperative protocols\n* Pregnancy or breastfeeding women\n* Informed consent not accepted",{"count":195,"type":22},52,"Specific Aims :\n\nThe aim of this prospective randomized controlled single-blind clinical trial was to evaluate the safety and efficacy of autologous microfragmented lipoaspirate tissue in arthroscopic rotator cuff repair.\n\nThe primary goal of this study was to test the following hypothesis: an intraoperative injection of autologous microfragmented adipose tissue processed with an enzyme-free technology could improve the clinical outcomes of single-row arthroscopic rotator cuff repair in terms of points in the Constant-Murley score (CMS) collected at least 5 years after surgery.\n\nBackground and Significance:\n\nRotator cuff surgery was initially proposed at the end of the 19th century and evolved then from open to arthroscopic techniques, rising quickly from a minor niche to a fully recognized subspecialty.\n\nTo improve clinical and functional results and reduce the retear rate, new fixation techniques and biological solutions to enhance tendon healing are being developed at a fast pace, as shown by the dramatic increase in the number of articles published per year.\n\nBiological solutions to enhance rotator cuff healing include growth factors and platelet-rich plasma, as well as mesenchymal stem cells (MSCs) and their derivatives.\n\nMSCs are believed to enhance tissue healing mainly through stimulation of local cells via paracrine mechanisms and anti-inflammatory and\u002For immunomodulatory activity, thus creating a suitable microenvironment for tissue repair.\n\nAutologous microfragmented lipoaspirate tissue has been recently introduced in orthopaedics as an easily available source of adipose derived MSCs (ADSCs) to support and accelerate tissue regeneration. Lipoaspirates contain human ADSCs and produce growth factors, such as platelet-derived growth factor, fibroblast growth factor, transforming growth factor beta, and vascular endothelial growth factor, which play important regulatory roles in cellular functions, including adhesion, chemotaxis, proliferation, migration, matrix synthesis, differentiation, and angiogenesis.\n\nHerewith, autologous microfragmented lipoaspirate tissue is expected to optimize the microenvironment for tendon regeneration. Among many approaches, devices relying on nonenzymatic methods and avoiding the use of additives and other additional manipulations (eg, centrifugation) allow one to harvest, process, and obtain autologous microfragmented lipoaspirate tissue directly in the operative theatre under sterile conditions. This permits immediate use in the same surgical intervention without delays owing to the difficulty of an ex vivo cell expansion and the complexity of the current good manufacturing practice requirements for preparing cells for therapeutic use.\n\nAlthough several animal studies have been published showing promising results for the use of ADSCs in enhancing the healing of rotator cuff tears, minimal evidence describing augmentation of rotator cuff treatment with lipoaspirate.\n\nPreliminary Studies\u002FProgress Report:\n\nThis study is a prospective, randomized, double-blind, controlled clinical trial and represents the final follow-up of an our previous study with short follow-up (2 years). The previous study demonstrated that the intraoperative injection of autologous microfragmented adipose tissue is safe and effective in improving short-term clinical and functional results after single-row arthroscopic rotator cuff repair.\n\nNevertheless, no significant differences emerged between the groups in terms of rerupture rate, complication rate, number of adverse events, and mid-term clinical outcomes.\n\nA previous in vitro study showed that autologous microfragmented adipose tissue significantly increases the proliferation rate of human tendon stem cells without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process.\n\nResearch Design and Method:\n\nAt least 5 years after surgery, all enrolled patients in the previous study will be call again and will be asked to complete the ASES, SST, and VAS questionnaire and they will undergo a clinical examination, including the CMS and measurement of isometric strength in shoulder forward flexion, abduction, and external rotation. All strength measures will be performed in triplicate with a dynamometer.\n\nDuring the same assessment day, the patients would be evaluated with MRI of the operated shoulder in order to assess tendon integrity and calculate rerupture rate according to the classification proposed by Sugaya (types IV and V defined as retears). Atrophy of the supraspinatus muscle belly was evaluated according to Warner and fatty degeneration was classified according to Fuchs.",[198,199,200],"Arthroscopic Rotator Cuff Repair","Augmentation","Microfragmented Adipose Tissue",{"date":131,"type":39},{"date":203,"type":39},"2025-04-11",{"date":205,"type":22},"2026-10-11",{"name":45,"class":46},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":216,"conditions":217,"keywords":228,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100629572","oral-health-dento-facial-condition-and-ohrqol-in-subjects-with-mowat-wilson-syndrome-an-epidemiologic-study-100629572","NCT07476417","Oral Health, Dento-facial Condition and OHRQoL in Subjects With Mowat-Wilson Syndrome: an Epidemiologic Study.","ORALMOWAT26","Inclusion Criteria:\n\n* individuals affected by MWS with confirmed molecularly diagnosis of ZEB2 gene variation.\n* written informed consent statement signed by parents\u002Flegal guardians for participation in the study\n\nExclusion Criteria:\n\n* individuals not affected by MWS\n* refusal of parents\u002Flegal guardians to participate in the study",{"count":215,"type":22},25,"Mowat-Wilson Syndrome (MWS) is a rare syndrome characterized by the presence of facial gestalt and delayed psychomotor development, variably associated with intellectual disability, epilepsy, Hirschsprung's disease (HSCR) and multiple congenital malformations.\n\nAlthough there is evidence of the presence of dental and craniofacial anomalies in MWS, little epidemiological data is available to date.\n\nThe goal of this observational study is to assess oral health and dento-facial phenotype of people affected by Mowat-Wilson Syndrome (MWS). In addition, the Oral Health Related Quality of Life (OHRQoL) will be investigated.",[218,219,220,221,222,223,224,225,226,227],"Mowat-Wilson Syndrome","Dental Caries","Periodontal Diseases","Sleep Related Breathing Disorder","Tooth Diseases","Malocclusion","Tooth Abnormalities","Oral Health Related Quality of Life (OHRQoL)","Craniofacial Abnormalities","Oral Mucosal Disease",[229,230,231,232,233,226],"Mowat-Wilson syndrome","dental caries","periodontal diseases","malocclusion","oral health","2026-03-19",{"date":236,"type":39},"2026-03-24",{"date":238,"type":22},"2026-04-01",{"date":240,"type":22},"2026-08-30",{"name":45,"class":46},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":78},"100616952","small-airways-disease-functional-assessment-in-idiopathic-pulmonary-fibrosis-swift-ipf-100616952","NCT07312305","Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)","SWIFT-IPF","Inclusion Criteria:\n\n* Age over 18 years\n* IPF of any degree of severity, diagnosed according to the 2022 ATS\u002FERS\u002FJRS\u002FALAT guidelines\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patients unable to provide informed consent for participation in the study\n* IPF exacerbation in the 6 months prior to enrollment\n* Previous diagnosis of chronic airway disease (e.g., bronchial asthma, chronic obstructive bronchitis, bronchiectasis with a cause other than IPF)\n* Presence of bronchial obstruction defined by an FEV1\u002FFVC (or FEV1\u002FVC) ratio below the lower limit of normal\n* Chronic therapy with long-acting bronchodilators or combinations of bronchodilators and inhaled corticosteroids\n* Inability of the patient to perform reproducible pulmonary function tests\n* Chronic treatment with systemic corticosteroids or immunosuppressants\n* Concomitant lung or pleural cancer\n* Pregnancy or breastfeeding women",{"count":250,"type":22},100,"Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis. Antifibrotic therapy can slow the progression of the disease and reduce mortality, but the life expectancy is less than 7-10 years in the vast majority of patients with IPF. There are no studies in the literature that have evaluated the presence of small airway disease in patients with IPF prior to the initiation of pharmacological therapy, using the nitrogen washout test. This test is currently considered the only non-invasive method capable of detecting ventilation inhomogeneity and closing volume, which are indicators of small airway dysfunction. The investigators carried out an Italian prospective, observational, multicenter study with the primary aim to assess the prevalence of small airway disease measured by the nitrogen washout test (evaluating the following functional parameters: phase 3 slope, closing volume, closing capacity, closing volume\u002Fvital capacity, closing capacity\u002Ftotal lung capacity, and phase 4 slope) in a group of patients with IPF at the time of diagnosis, before the initiation of antifibrotic therapy. During outpatients visits clinical, functional and radiological data will be collected. Results will be compared to an healthy control group matched with IPF population. Variations in small airways disease parameters will be assessed after one year of antifibrotic treatment.",[253,254],"Idiopathic Pulmonary Fibrosis","Small Airways Disease",[256,257,258],"IPF","SAD","SBW-N₂","2026-01-26",{"date":261,"type":39},"2026-01-28",{"date":263,"type":39},"2025-05-15",{"date":265,"type":22},"2027-05-15",{"name":45,"class":46},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":17,"sex":274,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":47},"100616380","role-of-extracellular-vesicles-as-biomarkers-of-pulmonary-involvement-in-patients-with-lymphangioleiomyomatosis-and-tuberous-sclerosis-complex-100616380","NCT07304856","Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex","Prospective Observational Study of the Role of Extracellular Vesicles (EVs) as Biomarkers of Pulmonary Involvement in Patients With Sporadic Lymphangioleiomyomatosis (S-LAM) and Tuberous Sclerosis Complex-Associated LAM (TSC-LAM)","Inclusion Criteria:\n\nFemale participants aged ≥18 years Confirmed diagnosis of tuberous sclerosis complex (TSC) and\u002For lymphangioleiomyomatosis (definite diagnosis of TSC-LAM or S-LAM) Follow-up at the Pulmonology Unit of ASST Santi Paolo e Carlo, Milan Ability to provide written informed consent\n\nExclusion Criteria:\n\nDiagnosis of \"probable\" or \"possible\" LAM Refusal to provide written informed consent","FEMALE","80 Years",{"count":277,"type":22},80,"Lymphangioleiomyomatosis (LAM) is a rare lung disease, linked to Tuberous Sclerosis Complex (TSC) or occurring sporadically, and involves abnormal mTORC1 activation. LAM cells are neoplastic, and recent focus has turned to extracellular vesicles (EVs), which mediate tumor progression and may serve as biomarkers. This study, conducted at the Pulmonology Unit of ASST Santi Paolo e Carlo and the Pharmacology Laboratory of the University of Milan, will analyze the characteristics of serum EVs in patients with LAM and TSC. During scheduled outpatient visits, clinical and functional data and blood samples will be collected. Plasma will be separated, and EVs will be isolated via centrifugation. EVs will be analyzed for size, concentration, and molecular content (proteins, lipids, nucleic acids). The results obtained will be collected and correlated with the clinical and functional data.",[280,281],"Lymphangioleiomyomatosis (LAM)","Extracellular Vesicles; Generation and Function",[283],"LAM, TSC, EVs","2025-12-12",{"date":286,"type":39},"2025-12-26",{"date":288,"type":39},"2025-04-16",{"date":290,"type":22},"2026-08-20",{"name":45,"class":46},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":58,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":47},"100612924","fmri-study-on-dctmd-patients-100612924","NCT07259902","FMRI Study on DC\u002FTMD Patients","Mapping the Neuroplasticity of Patients Affected by Chronic Temporomandibular Disorders on fMRI","Inclusion Criteria:\n\n* Afflicted with temporomandibular disorder (TMD) associated with chronic pain diagnosed by an experienced specialist among the authors; the disorder, to be considered chronic, must have been present for at least six months.\n* Patients with adequate sensorimotor abilities to participate in the study. This included sufficient vision to read from a computer or tablet screen at a normal distance, sufficient hearing ability to understand normal language, and sufficient motor ability to control a table mouse or computer.\n\nExclusion Criteria:\n\n* Control subjects, participating voluntarily in the study, must have met the following inclusion criteria:\n* Healthy subjects defined as free from temporomandibular disorders or diagnosed psychological and\u002For psychiatric disorders.",{"count":300,"type":22},60,[60],"Temporomandibular disorders (TMD) are among the most common causes of chronic pain worldwide. It is estimated that about 5-12% of the global population is affected, and some conditions, such as arthritis, may be causative factors. Depending on severity, the joints involved can affect multiple functions of the masticatory system, such as the ability to speak, chew, swallow, limit facial expressions, and even breathe. Moreover, most patients with TMD may report painful conditions in other parts of the body, with comorbidities including chronic fatigue syndrome, chronic headache, endometriosis, fibromyalgia, interstitial cystitis, irritable bowel syndrome, back pain, sleep disorders, and vulvodynia. Another significant condition that frequently occurs alongside TMD is psychological distress in the form of anxiety and\u002For depression.\n\nThe study proposed by this research protocol aims to investigate the presence of TMD and associated psychological\u002Fpsychiatric disorders such as anxiety and depression. The innovative value of the research lies in evaluating whether the association between these disorders may lead to neuroplastic changes at the brain level, which could guide targeted therapies. Only a few studies in the literature have explored this possible association, with inconclusive and conflicting results.\n\nThe study will be prospective in design, based on reference clinical\u002Fdiagnostic criteria and functional neuroimaging.",[304],"TMJ Disorder","2025-11-27",{"date":307,"type":39},"2025-12-02",{"date":309,"type":22},"2026-01-01",{"date":311,"type":22},"2031-01-01",{"name":45,"class":46},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":58,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":47},"100593007","efficacy-of-corrective-rubber-insoles-in-healthcare-professionals-with-foot-overpronation-100593007","NCT07000838","Efficacy of Corrective Rubber Insoles in Healthcare Professionals With Foot Overpronation","Evaluation of the Efficacy of Corrective Rubber Insoles in a Population of Healthcare Professionals With Foot Overpronation","Inclusion Criteria:\n\n* Healthworker (attendings, residents, OR nurses, ER nurses, therapists...)\n* Maximum age inferior to 65 y.o. at recruitment time\n* Partecipants stands from 60% to 80% of their working time\n* Uses mostly healthcare shoes while working\n* Hyperpronation condition\n* No other pathologic condition of the feet\n* Partecipants accept to wear medially wedged orthesis for at least 3 months\n* Signatures of consensus to join the study\n* Partecipants must be aware of the implication of the study\n\nExclusion Criteria:\n\n* Other pathologic condition of the foot\n* Age superiore to 65 y.o. at the recruitment time","65 Years",{"count":195,"type":22},[60],"Foot hyperpronation is a common postural condition that can lead to pain, deformities (such as hallux valgus), and muscular issues. This problem is especially relevant among adults who spend long hours standing, such as healthcare workers. Custom-made foot orthoses with a medial wedge have proven effective in improving comfort and correcting certain biomechanical alterations, even in asymptomatic individuals.\n\nThe study described has two main objectives:\n\n* to validate the Italian version of the Foot Health Status Questionnaire (FHSQ), already validated in English and Spanish, by assessing its reliability and reproducibility as a tool to measure foot health.\n* through a pilot study, to analyze the effects of using specific professional footwear in healthcare workers with hyperpronation, evaluating perceived benefits in terms of pain reduction and postural improvement.",[325,326,327],"Hyperpronation","Overpronation","Pes Planus","2025-05-22",{"date":330,"type":39},"2025-06-03",{"date":332,"type":39},"2025-05-09",{"date":334,"type":22},"2026-09-18",{"name":45,"class":46},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":58,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":47},"100581087","muscle-aging-evaluation-100581087","NCT06845748","Muscle Aging Evaluation","Assessment of Physical and Physiological Changes in Muscle Aging","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Must be able to engage in physical activity as prescribed in the study protocol.\n* No pre-existing musculoskeletal conditions that would prevent safe participation.\n* No history of hospitalization in the six weeks prior to enrollment.\n* No acute or uncontrolled medical conditions that could interfere with exercise participation.\n* Willing to sign an informed consent form before participation.\n\nExclusion Criteria:\n\n* Severe Medical Conditions (cardiovascular diseases, severe respiratory diseases, neurological disorders)\n* Cognitive and Psychological Conditions (severe cognitive impairment or dementia, psychiatric disorders)\n* Pregnancy\n* Use of anabolic or muscle-enhancing substances (use of steroids, testosterone therapy, or other performance-enhancing drugs within the past 6 months)\n* Participation in ther Clinical Trials",{"count":344,"type":22},200,[60],"This study aims to assess the effects of physical activity in counteracting muscle aging. The increasing life expectancy worldwide has led to a rise in age-related muscle decline, which negatively impacts strength, function, and overall quality of life. Sedentary lifestyles further accelerate this process, increasing the risk of frailty, falls, fractures, and disability.\n\nThis randomized controlled trial (RCT) will investigate whether a structured exercise program can help reduce muscle deterioration. The study will involve 200 participants, divided into three age groups: i) Young adults (18-35 years); ii) Middle-aged adults (35-65 years); iii) Older adults (\\>65 years).\n\nParticipants will be assigned to either a physical activity intervention group or a control group. The intervention group will follow a 48-week structured program including, muscle-strengthening sessions (bodyweight exercises at home) and aerobic sessions (moderate-intensity cardio exercise). The control group will not receive any exercise prescription.\n\nThe primary objective is to evaluate whether physical activity improves muscle strength, measured through handgrip strength at 12 and 48 weeks.\n\nSecondary objectives include: i) assessing changes in muscle mass, function, and quality of life; ii) measuring improvements in physical performance (aerobic capacity, balance, and mobility tests); iii) evaluating psychological and cognitive well-being.\n\nThis 48-week trial will consist of: i) baseline assessments (body composition, strength tests, physical and cognitive evaluations); ii) intervention period (12 weeks of structured training for the experimental group); iii) follow-up assessments (at 12 and 48 weeks).\n\nAll participants will undergo periodic evaluations, including anthropometric and body composition measurements (weight, BMI, muscle mass), aerobic and muscle strength tests (handgrip, knee extension, 1-rep max tests), functional mobility assessments (six-minute walking test, chair-stand test), psychological and cognitive evaluations (mood profiles, quality of life surveys, cognitive tests).\n\nEngaging in regular exercise may help participants: i) maintain muscle mass and strength; ii) improve physical function and balance; iii) enhance overall well-being and independence; iv) reduce the risk of age-related disabilities.\n\nAdditionally, the study aims to provide valuable insights into the role of exercise in healthy aging, helping healthcare providers develop personalized interventions for older adults.",[348],"Preventing Age-Related Muscle Loss: the Role of Exercise in Improving Strength, Function, and Well-being",[350,351,352,353,354],"sarcopenia","aging","Frailty prevention","Exercise","interventional study","2025-02-19",{"date":357,"type":39},"2025-02-25",{"date":359,"type":22},"2025-04",{"date":361,"type":22},"2027-10",{"name":45,"class":46},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":18,"minAge":370,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":58,"phases":373,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":47},"100576783","phase-2-cornelia-de-lange-syndrome-assessing-positive-effects-of-lithium-treatment-100576783","NCT06789783","Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment","CLoSER","Inclusion Criteria:\n\n* Age \\> 4 years\n* Body weight within the normal range in the reference range for CdLS, based on age and height\n* Diagnosis of CdLS based on consensus clinical criteria and a confirmed mutation in the NIPBL gene\n* Stable drug regimen for 4 weeks prior to starting the study\n* Written consent signed by parent\u002Flegal guardian\u002Frepresentative prior to the screening visit\n* Ability to take the study drug provided in capsules or drops (for younger patients and those with swallowing difficulties) or combined with food\u002Fdrinks\n* Caregiver must be able to understand the instructions and participate knowingly in the study\n\nExclusion Criteria:\n\n* The patient is participating in another clinical trial\n* QT interval prolongation, thyroid dysfunction, renal insufficiency, hepatic insufficiency, leukopenia, or other currently clinically significant medical disorders (as determined by the investigator), other than those directly related to CdLS\n* QTcF interval on ECG greater than 450 msec\n* Severe diabetes mellitus or inherited metabolic disorder","4 Years",{"count":372,"type":22},34,[374,375],"PHASE2","PHASE3","The study \"Cornelia de Lange Syndrome: assessing positive effects of Lithium treatment - CLoSER\" aims to evaluate the effectiveness on behavioral modifications of lithium carbonate therapy in patients with Cornelia de Lange syndrome (CdLS).\n\nCdLS is a rare genetic disease caused by autosomal mutations dominant or X-linked. The prevalence of CdLS is estimated to be between 1:10,000-30,000 newborns, but it is probably underestimated because the most cases mild ones may go undiagnosed. This syndrome is characterized by slow growth before and after birth with intellectual disability and short stature, from major malformations such as facial anomalies, neurological disorders, gastrointestinal and musculoskeletal malformations. To date, for these patients only targeted medical and surgical therapeutic interventions are recommended for improving the quality of life. No drug therapy is validated for the cognitive\u002Fbehavioral disorders. It has been shown that lihium-dependent activation of the WNT pathway is able to recover the Abnormal phenotype in many CdLS models. Lithium is already widely used in psychiatry and has a long history of clinical efficacy.\n\nRecently some studies are evaluating the effect of lithium in patients with characteristics common to CdLS showing promising results . This trial intends to transfer the preliminary data obtained from in vitro and in vivo studies on patients with CdLS.\n\nGiven the currently untreatable nature of the syndrome, this treatment could represent a possible therapeutic strategy aimed at improving the behavioral and intellectual disabilities typical of CdLS.",[378],"Cornelia De Lange Syndrome",[380],"Lithium treatment","2025-01-23",{"date":383,"type":39},"2025-01-28",{"date":385,"type":39},"2024-05-01",{"date":387,"type":22},"2026-12",{"name":45,"class":46},{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":413},"100487983","utility-of-bronchoscopy-in-patients-with-haemoptysis-and-negative-chest-ct-scan-ulysses-100487983","NCT05634200","Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES)","Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan: an Observational, Prospective, Multicentre Study (ULYSSES)","Inclusion Criteria:\n\n* ≥18 years old\n* Haemoptysis of unknown origin\n* Negative or non-diagnostic chest CT scan\n\nExclusion Criteria:\n\n* Known bleeding lesions of the upper or lower respiratory airways\n* Chest CT scan diagnostic for hemoptysis etiology\n* Refusal to sign the informed consent\n* Refusal of bronchoscopy",{"count":397,"type":22},150,"Conflicting evidence exist in the literature on the utility of bronchoscopy in patients with haemoptysis and negative\u002Fnon-diagnostic chest CT scan.\n\nThe primary aim of this prospective, observational, multicenter study is to evaluate the utility of bronchoscopy in patients with haemoptysis and negative\u002Fnon-diagnostic CT scans. Secondary aims are related to the utility of bronchoscopy to detect occult malignancies, the source of the bleeding and the clinical features of the cohort",[400],"Hemoptysis",[402,92,403,404,405],"Computed tomography","Lung cancer","CT scan","Haemoptysis","2024-08-19",{"date":408,"type":39},"2024-08-21",{"date":410,"type":39},"2022-10-01",{"date":183,"type":22},{"name":45,"class":46},14,{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":18,"minAge":422,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":58,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":47},"100550560","targeting-the-gut-to-improve-seizure-control-in-cdkl5-deficiency-disorder-cdd-100550560","NCT06448663","Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)","Targeting the Gut to Improve Seizure Control in CDD","NUTRIENT","Inclusion Criteria:\n\nclinical diagnosis of CDD and demonstrated CDKL5 pathogenic variant; drug-resistant seizures; ensured participation of a caregiver; willingness to sign the informed consent.\n\nExclusion Criteria:\n\norganic GI disorders (i.e., food allergies, celiac disease); special diets; percutaneous endoscopic gastrostomy tube; use of antibiotics or probiotics in the previous month.","3 Years","50 Years",{"count":5,"type":22},[60],"Standard anti-seizure medications have limited efficacy in seizure control in cyclin-dependent kinase-like 5 deficiency disorder (CDD).\n\nThe study will investigate whether targeting the gut-microbiota-brain axis in CDD patients can alleviate seizures and ameliorate other comorbidities.",[428],"CDKL5",[430],"epilepsy, gut microbiota, sleep disorders","2024-06-03",{"date":433,"type":39},"2024-06-07",{"date":435,"type":39},"2024-04-01",{"date":437,"type":22},"2025-04-30",{"name":45,"class":46},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":58,"phases":447,"briefSummary":448,"conditions":449,"keywords":452,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100545424","personalized-rendering-of-motor-system-functional-plasticity-potential-to-improve-glioma-resection-and-quality-of-life-100545424","NCT06381726","Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life","Inclusion Criteria (ARM 1):\n\n* Patients signing informed consent for participation in the study\n* Males and females\n* Age ≥ 18 years\n* Patients with lower-grade gliomas with involvement of the motor pathways who are candidates for surgery\n\nInclusion Criteria (ARM 2\u002F3\u002F4):\n\n* Patients signing informed consent for participation in the study\n* Males and females\n* Age ≥ 18 years\n* Patients with lower-grade gliomas treated over two years with tumors only biopsied and\u002For partially resected and eligible for second surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Inability to adhere to standard study controls\n* Subjects unable to understand and freely provide consent to the study",{"count":446,"type":22},400,[60],"Background Lower-grade-gliomas affect young patients, thus the longest progression-free-survival (PFS) with a high level quality of life is crucial. Surgery most significantly impacts on tumor natural history, postponing recurrence, improving symptoms, decreasing the need of adjuvant therapies, with extent of resection, gross-total and supra-total (GTR and STR), strongly associating with longest PFS. Achievement of GTR or STR depends on the degree of functional reorganization induced by glioma. Consequently, a successful treatment fostering neural circuit reorganization before surgery, would increase the chance of GRT\u002FSTR.\n\nHypothesis The plastic potential of motor system suggests that reorganization of circuits controlling hand movements could be presurgically fostered in LGG patients by enhancing plasticity with up-front motor-rehabilitation and\u002For by decreasing tumor infiltration with up-front chemotherapy. Advanced neuroimaging allows to infer the neuroplasticity potential. Intraoperative assessment of the motor circuits functionality will validate reliability of preoperative analyses.\n\nAims The project has 4 aims, investigating: A) the presurgical functional (FC) and structural (SC) connectomics of the hand-motor network to picture the spontaneous reorganization and the influence of clinical, imaging and histomolecular variables; B) the dynamic of FC and SC after tumor resection; C) changes in FC and SC maps after personalized upfront motor rehabilitation and\u002For chemotherapy; D) the effect of FC and SC upfront treatment on the achievement of GTR\u002FSTR preserving hand dexterity.\n\nExperimental Design Resting-state fMRI and diffusion-MRI will provide FC and SC maps pre- and post-surgery; personalized up-front motor rehabilitation and\u002For chemotherapy will be administered; Intraoperative brain mapping procedures will generate data to validate the maps.\n\nExpected Results\n\n1. Provide a tool to render the motor functional reorganization predictive of surgical outcome.\n2. Identify demographic, clinical and imaging variables associated with functional reorganization.\n3. Describe the gain induced by up-front treatment.\n4. Distinguish \"patterns\" predicting chance for GTR\u002FSTR from \"patterns\" suggesting need for up-front treatment.\n\nImpact On Cancer Results will increase the achievement of GTR\u002FSTR, preserving motor integrity, with dramatic impact on LGGs natural history.",[450,451],"Glioma","Glioma, Malignant",[450,453,454,455,456,457,458,459,460,461,462,463,464,465],"Neurosurgery","Chemotherapy, Neoadjuvant","Motor Rehabilitation","Magnetic Resonance Imaging","Diffusion Magnetic Resonance Imaging","Resting State Functional Magnetic Resonance Imaging","Functional Magnetic Resonance Imaging","Functional Connectomics","Structural Connectomics","Neuronal Plasticity","Higher Nervous Activity","Neurological Rehabilitation","Antineoplastic Protocols","2024-04-18",{"date":468,"type":39},"2024-04-24",{"date":470,"type":39},"2024-03-07",{"date":472,"type":22},"2028-02-28",{"name":45,"class":46},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":18,"minAge":482,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":58,"phases":486,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":47},"100456117","phase-2-effects-of-sitagliptin-in-relatives-of-t1d-patients-100456117","NCT05219409","Effects of Sitagliptin in Relatives of T1D Patients","Effects of Sitagliptin in Relatives of Patients With Type 1 Diabetes Mellitus, at High Risk of Developing the Disease","SITA-one","Inclusion Criteria:\n\n* Age of the subject between 10 and 45 years\n* Subject (or legal guardian in the case of a minor) is able to provide informed consent\n* If a first degree relative of the proband with T1D must be between 6 and 45 years old (brother, sister, parent, child)\n* If a relative of the proband with T1D is second degree, he must be between 6 and 20 years old (nephew, uncle, aunt, grandfather, grandmother, cousin)\n* Presence of at least two autoantibodies associated with diabetes\n* Impaired glucose tolerance on the OGTT test (fasting glucose greater than 110 mg\u002Fdl but less than 126 mg\u002Fdl or 2-hour glucose greater than or equal to 140 mg\u002Fdl but less than 200 mg\u002Fdl or 'OGTT at 30', 60 ', 90' greater than or equal to 200 mg\u002Fdl)\n* If the subject is a female with reproductive potential, she must have a negative pregnancy test at the enrollment visit and must agree not to seek pregnancy for at least one year from randomization\n* If the subject is male, he must agree not to seek pregnancies with any partner for at least one year from the randomization\n* The subject must agree to renounce other types of trials during this study\n* Weight at the time of recruitment of at least 26 kg\n* It must be favorable and clinically acceptable to postpone vaccinations with live and attenuated agents for at least one year after treatment\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus previously diagnosed or diagnosed during screening investigations\n* Serological evidence of current or past HIV, Hepatitis C, Hepatitis B\n* Changes in blood counts, INR or liver enzymes\n* Being pregnant or breastfeeding\n* Evidence of pancreatic changes in the laboratory\n* Having undergone a previous experimental treatment for Type 1 Diabetes Mellitus\n* Chronic Renal Failure stage IIIa onwards (eGFR \\\u003C45 ml \u002F min \u002F 1.7 m2)\n* History of previous pancreatitis\n* Lymphopenia (\\\u003C1000 lymphocytes \u002F µL)\n* Neutropenia (\\\u003C1500 PMN \u002F µL)\n* Thrombocytopenia (\\\u003C150,000 platelets \u002F µL)\n* Anemia (Hgb \\\u003C10 grams \u002F deciliter \\[g \u002F dL\\])\n* AST or ALT\\> 1.5 x ULN\n* Total bilirubin\\> 1.5 x upper limit of normal (ULN) with the exception of subjects diagnosed with Gilbert's syndrome who may be eligible provided they have no other cause leading to hyperbilirubinemia\n* INR\\> 0.1 above the upper limit of the norm at the laboratory of the participating center\n* Alterations of Amylase and Lipase due to the pancreas\n* Chronic active infection other than localized skin infections\n* A positive PPD test\n* Vaccination with a live virus within 8 weeks of randomization\n* Vaccination with a killed virus within 4 weeks of randomization\n* Laboratory or clinical evidence of acute EBV or CMV infection\n* Serological evidence of current or past HIV, hepatitis B or hepatitis C infection\n* Being currently pregnant or breastfeeding, or planning to become pregnant\n* Chronic use of steroids or other immunosuppressive agents\n* A history of asthma or atopic disease that requires chronic treatment\n* Untreated hypothyroidism or active Graves' disease at randomization\n* Current use of non-insulin drugs that affect glycemic control\n* Previous OKT®3 or other anti-CD3 treatment\n* Administration of a monoclonal antibody within the year prior to randomization\n* Participation in any type of clinical trial of therapeutic drugs or vaccines in the 12 weeks prior to randomization\n* Any conditions that, in the opinion of the investigator, could interfere with the conduct of the study or with the safety of the subject.","10 Years","45 Years",{"count":485,"type":22},70,[374,375],"Type 1 Diabetes (T1D) is a chronic autoimmune disease, with a genetic background, resulting from the immune-mediated destruction of beta cells of the pancreas. It can lead to fatal short-term and long-term complications, especially if it is diagnosed late. Three stages of the disease can be identified: Stage 1 is defined by the presence of two or more anti-islet autoantibodies (GAD65, ICA, IA-2, ZnT8) with normoglycemia, Stage 2 shows progression to dysglycemia (impaired glucose tolerance) in the setting of two or more anti-islet autoantibodies, Stage 3 occurs when a patient meets ADA criteria for the diagnosis of diabetes. It's been demonstrated that Teplizumab (an Fc receptor nonbinding anti-CD3 monoclonal antibody) delays the transition from pre-symptomatic T1D (stage 2) to overt T1D (stage 3). Also Sitagliptin, a DPP4 inhibitor, has been proved effective in inhibiting inflammation in T1D both in vitro in T1D mice, and in vivo in Latent autoimmune diabetes in adults (LADA) patients. Furthermore, it has been confirmed that Sitagliptin reduces the prevalence of worse forms of acute GVHD after myeloablative allogeneic hematopoietic stem-cell transplantation.\n\nThe study aims to investigate if Sitagliptin can have a delaying effect on progression to overt T1D, on the account of its anti-inflammatory properties. The cohort is made of screened relatives of T1D patients, who are classified as high-risk of developing T1D.\n\nScreening relatives of T1D patients for dysglycemia and anti-islet autoantibodies. Selecting the patients in Stage 2 Pre-symptomatic T1D (dysglycemia and at least two types of autoantibodies) and then beginning therapy with Sitagliptin, while monitoring their glucose metabolism with a Continuous Glucose Monitoring (CGM) system.",[489],"Type 1 Diabetes",[491],"Sitagliptin","2023-05-09",{"date":494,"type":39},"2023-05-10",{"date":496,"type":22},"2023-07",{"date":498,"type":22},"2027-12",{"name":45,"class":46},{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":507,"targetDuration":4,"studyType":58,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":47},"100503677","phase-4-immediate-versus-delayed-loading-of-single-posterior-zirconia-implants-100503677","NCT05838365","Immediate Versus Delayed Loading of Single Posterior Zirconia Implants","Immediate Versus Delayed Loading of Single Posterior Zirconia Implants: A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Sistemically healthy patients\n* partial edentulism\n* premolar position\n* molar position\n* Bone width and height at least 6 and 10mm, respectively.\n* Keratinized tissue, at least 1 mm at implant site\n* Full understanding of the proposed surgical treatments and the protocol schedule\n* Full comprehension and availability to sign the informed consent form\n\nExclusion Criteria:\n\n* Heavy smokers (\\>10 cigarettes a day)\n* Serious kidney or liver diseases\n* Uncontrolled diabetes\n* Bisphosphonates intake\n* History of radiotherapy of the head and neck\n* Current antiblastic chemotherapy\n* Congenital (primary) or acquired (secondary) immunodeficiency\n* Pregnant women\n* Connective tissue disorders\n\nLocal exclusion criteria:\n\n* untreated stage III\u002FIV periodontitis\n* Autoimmune diseases\n* oral parafunctions",{"count":508,"type":22},220,[150],"The main aim of the present study is to investigate implant success rate after 5 years of function of immediate (Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement) loading of two-pieces zirconia implant, placed in pristine bone without bone regeneration. Implant success rate will be defined according to Buser's criteria. Secondary endpoints: Marginal bone level (MBL) evaluation by means of standardized radiographs; Clinical evaluation of biological (e.g. Plaque Index, PI; Probing Pocket Depth, PPD, Bleeding on Probing, BOP; suppuration upon probing\u002Fpalpation) and prosthetic\u002Ftechnical complications; Clinical evaluation of soft tissue width, keratinized tissue, marginal and interproximal soft tissue recession; Patient reported outcome measures (PROMs) by questionnaire administration:",[512,513,514],"Dental Implant Failed","Peri-implant Mucositis","Peri-Implantitis","2023-04-26",{"date":517,"type":39},"2023-05-01",{"date":519,"type":39},"2022-12-01",{"date":521,"type":22},"2029-06-01",{"name":45,"class":46},{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":58,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":47},"100444939","keratized-mucosa-in-cg-implant-placement-ctg-vs-flapless-100444939","NCT05073952","Keratized Mucosa in CG Implant Placement: CTG vs Flapless","Width of Keratinazed Mucosa in Immediately Loaded Posterior Implant Restorations Treated With Different Surgical Approaches: Randomized Clinical Study.","Inclusion Criteria:\n\n* Age 18+\n* Patients with partial edentulism in the posterior region (4-7) upper or lower for at least 3 months\n* Patient whose tomographic examination shows adequate bone volumes for computer guided placement of a standard diameter implant (\\> 3.5 mm) without the need for bone regeneration procedures\n* Patients who have accepted informed consent and participation in the study\n* Patients who do not have exclusion criteria\n\nEclusion Criteria\n\n* Patients who refuse to co-operate\n* Systemic conditions of exclusion:\n\n  * Medical conditions requiring prolonged use of steroids\n  * Severe hemophilia\n  * In therapy with intravenous bisphosphonates\n  * History of white blood cell dysfunction or deficiency\n  * History of head and neck radiotherapy or chemotherapy\n  * History of kidney failure\n  * Pregnant or breastfeeding patient\n  * History of uncontrolled endocrine disorders\n  * Physical handicaps that hinder proper oral hygiene\n  * Use of experimental devices or drugs within 30 days prior to implant placement surgery\n  * Alcoholism or drug abuse\n  * Smokers of\\> 10 cigarettes per day or the equivalent cigar or\\> 10 tobacco-based chewings per day\n  * Conditions or circumstances that prevent the completion of participation in the study or interfere with the analysis of the study results\n\nLocal exclusion conditions:\n\n* Local inflammation, including untreated periodontitis\n* Patients with erosive lichen planus\n* History of local radiation therapy\n* Presence of bone lesions\n* Unhealed extraction sites\n* History of bone reconstruction and bone grafting techniques in the sites where the implants are to be inserted\n* Bruxism\n* Bleeding index\\> 30% and number of pockets\\> 5mm greater than 10",{"count":531,"type":22},44,[60],"The present study will evaluate the difference in terms of keratinazed mucosa (KM) in computer guided implant placement with immediate loading, comparing a flapless approach to flap surgery with connective tissue graft.",[535],"Variation of Keratinized Mucosa After Implant Surgery",[537,538,539,540,541,542],"dental implant","Keratinized mucosa","Connective tissue graft","flapless implant placement","Computer guided implantology","Immediate loading","2021-12-02",{"date":545,"type":39},"2021-12-03",{"date":547,"type":39},"2021-10-18",{"date":549,"type":22},"2028-06-01",{"name":45,"class":46},""]